O	0	4	Five
O	4	5	-
O	5	9	year
O	10	17	outcome
O	18	21	for
O	22	27	women
O	28	38	randomised
O	39	41	in
O	42	43	a
O	44	49	phase
O	50	53	III
O	54	59	trial
O	60	69	comparing
B-intervention	70	81	doxorubicin
I-intervention	82	85	and
I-intervention	86	102	cyclophosphamide
O	103	107	with
B-control	108	119	doxorubicin
I-control	120	123	and
I-control	124	133	docetaxel
O	134	136	as
O	137	144	primary
O	145	152	medical
O	153	160	therapy
O	161	163	in
O	164	169	early
O	170	176	breast
O	177	183	cancer
O	183	184	:
O	185	187	an
O	188	193	Anglo
O	193	194	-
O	194	200	Celtic
O	201	212	Cooperative
O	213	221	Oncology
O	222	227	Group
O	228	233	study
O	233	234	.

O	235	237	To
O	238	245	compare
O	246	249	the
O	250	254	long
O	254	255	-
O	255	259	term
O	260	267	outcome
O	268	270	of
O	271	276	women
O	277	281	with
O	282	289	primary
O	290	292	or
O	293	300	locally
O	301	309	advanced
O	310	316	breast
O	317	323	cancer
O	324	334	randomised
O	335	337	to
O	338	345	receive
O	346	352	either
O	353	364	doxorubicin
O	365	368	and
O	369	385	cyclophosphamide
O	386	387	(
O	387	389	AC
O	389	390	)
O	391	393	or
O	394	405	doxorubicin
O	406	409	and
O	410	419	docetaxel
O	420	421	(
O	421	423	AD
O	423	424	)
O	425	427	as
O	428	435	primary
O	436	448	chemotherapy
O	448	449	.

O	450	458	Eligible
B-eligibility	459	467	patients
I-eligibility	468	472	with
I-eligibility	473	483	histologic
I-eligibility	483	484	-
I-eligibility	484	490	proven
I-eligibility	491	497	breast
I-eligibility	498	504	cancer
I-eligibility	505	509	with
I-eligibility	510	517	primary
I-eligibility	518	525	tumours
I-eligibility	526	527	>
I-eligibility	528	530	or
I-eligibility	531	532	=
I-eligibility	533	534	3
I-eligibility	535	537	cm
I-eligibility	537	538	,
I-eligibility	539	551	inflammatory
I-eligibility	552	554	or
I-eligibility	555	562	locally
I-eligibility	563	571	advanced
I-eligibility	572	579	disease
I-eligibility	579	580	,
I-eligibility	581	584	and
I-eligibility	585	587	no
I-eligibility	588	596	evidence
I-eligibility	597	599	of
I-eligibility	600	607	distant
I-eligibility	608	618	metastases
O	618	619	,
O	620	624	were
O	625	635	randomised
O	636	638	to
O	639	646	receive
O	647	648	a
O	649	656	maximum
O	657	659	of
O	660	661	6
O	662	668	cycles
O	669	671	of
O	672	678	either
O	679	690	doxorubicin
O	691	692	(
O	692	694	60
O	695	697	mg
O	697	698	/
O	698	699	m
O	699	700	(
O	700	701	2
O	701	702	)
O	702	703	)
O	704	708	plus
O	709	725	cyclophosphamide
O	726	727	(
O	727	730	600
O	731	733	mg
O	733	734	/
O	734	735	m
O	735	736	(
O	736	737	2
O	737	738	)
O	738	739	)
O	740	741	i
O	741	742	/
O	742	743	v
O	744	746	or
O	747	758	doxorubicin
O	759	760	(
O	760	762	50
O	763	765	mg
O	765	766	/
O	766	767	m
O	767	768	(
O	768	769	2
O	769	770	)
O	770	771	)
O	772	776	plus
O	777	786	docetaxel
O	787	788	(
O	788	790	75
O	791	793	mg
O	793	794	/
O	794	795	m
O	795	796	(
O	796	797	2
O	797	798	)
O	798	799	)
O	800	801	i
O	801	802	/
O	802	803	v
O	804	809	every
O	810	811	3
O	812	817	weeks
O	817	818	,
O	819	827	followed
O	828	830	by
O	831	838	surgery
O	839	841	on
O	842	852	completion
O	853	855	of
O	856	868	chemotherapy
O	868	869	.

O	870	878	Clinical
O	879	882	and
O	883	893	pathologic
O	894	903	responses
O	904	908	have
O	909	919	previously
O	920	924	been
O	925	933	reported
O	933	934	.

O	935	939	Time
O	940	942	to
O	943	950	relapse
O	950	951	,
O	952	956	site
O	957	959	of
O	960	967	relapse
O	967	968	,
O	969	972	and
O	973	976	all
O	976	977	-
O	977	982	cause
O	983	992	mortality
O	993	997	were
O	998	1006	recorded
O	1006	1007	.

O	1008	1012	This
O	1013	1020	updated
O	1021	1029	analysis
O	1030	1038	compares
O	1039	1043	long
O	1043	1044	-
O	1044	1048	term
O	1049	1056	disease
O	1056	1057	-
O	1057	1061	free
O	1062	1063	(
O	1063	1066	DFS
O	1066	1067	)
O	1068	1071	and
O	1072	1079	overall
O	1080	1088	survival
O	1089	1090	(
O	1090	1092	OS
O	1092	1093	)
O	1094	1099	using
O	1100	1110	stratified
O	1111	1114	log
O	1115	1119	rank
O	1120	1127	methods
O	1127	1128	.

O	1129	1130	A
O	1131	1136	total
O	1137	1139	of
B-total-participants	1140	1143	363
O	1144	1152	patients
O	1153	1157	were
O	1158	1168	randomised
O	1169	1171	to
O	1172	1174	AC
O	1175	1176	(
O	1176	1177	n
O	1178	1179	=
B-intervention-participants	1180	1183	181
O	1183	1184	)
O	1185	1187	or
O	1188	1190	AD
O	1191	1192	(
O	1192	1193	n
O	1194	1195	=
B-control-participants	1196	1199	182
O	1199	1200	)
O	1200	1201	.

O	1202	1203	A
B-outcome	1204	1212	complete
I-outcome	1213	1223	pathologic
I-outcome	1224	1232	response
O	1233	1236	was
O	1237	1245	observed
O	1246	1248	in
B-iv-bin-percent	1249	1251	16
I-iv-bin-percent	1251	1252	%
O	1253	1256	for
O	1257	1259	AC
O	1260	1263	and
B-cv-bin-percent	1264	1266	12
I-cv-bin-percent	1266	1267	%
O	1268	1271	for
O	1272	1274	AD
O	1275	1276	(
O	1276	1277	P
O	1278	1279	=
O	1280	1281	0
O	1281	1282	.
O	1282	1284	43
O	1284	1285	)
O	1285	1286	.

O	1287	1290	The
B-outcome	1291	1297	number
I-outcome	1298	1300	of
I-outcome	1301	1309	patients
I-outcome	1310	1314	with
I-outcome	1315	1323	positive
I-outcome	1324	1332	axillary
I-outcome	1333	1338	nodes
I-outcome	1339	1341	at
I-outcome	1342	1349	surgery
O	1350	1354	with
O	1355	1357	AC
O	1358	1361	was
B-iv-bin-percent	1362	1364	61
I-iv-bin-percent	1364	1365	%
O	1366	1369	and
O	1370	1372	AD
B-cv-bin-percent	1373	1375	66
I-cv-bin-percent	1375	1376	%
O	1377	1378	(
O	1378	1379	P
O	1380	1381	=
O	1382	1383	0
O	1383	1384	.
O	1384	1386	36
O	1386	1387	)
O	1387	1388	.

O	1389	1391	At
O	1392	1393	a
O	1394	1400	median
O	1401	1407	follow
O	1407	1408	-
O	1408	1410	up
O	1411	1413	of
O	1414	1416	99
O	1417	1423	months
O	1424	1429	there
O	1430	1432	is
O	1433	1435	no
O	1436	1447	significant
O	1448	1458	difference
O	1459	1466	between
O	1467	1470	the
O	1471	1474	two
O	1475	1481	groups
O	1482	1485	for
B-outcome	1486	1489	DFS
O	1490	1491	(
O	1491	1492	P
O	1493	1494	=
O	1495	1496	0
O	1496	1497	.
O	1497	1499	20
O	1499	1500	)
O	1501	1504	and
B-outcome	1505	1507	OS
O	1508	1509	(
O	1509	1510	P
O	1511	1512	=
O	1513	1514	0
O	1514	1515	.
O	1515	1517	24
O	1517	1518	)
O	1518	1519	.

B-outcome	1520	1526	Deaths
O	1527	1531	were
O	1532	1535	due
O	1536	1538	to
O	1539	1549	metastatic
O	1550	1556	breast
O	1557	1563	cancer
O	1564	1566	in
O	1567	1569	96
O	1569	1570	%
O	1571	1573	of
O	1574	1582	patients
O	1582	1583	.

O	1584	1587	Our
O	1588	1592	data
O	1593	1595	do
O	1596	1599	not
O	1600	1607	support
O	1608	1609	a
B-outcome	1610	1618	clinical
I-outcome	1619	1626	benefit
O	1627	1630	for
O	1631	1643	simultaneous
O	1644	1658	administration
O	1659	1661	of
O	1662	1664	AD
O	1665	1673	compared
O	1674	1678	with
O	1679	1681	AC
O	1681	1682	.

O	1683	1690	However
O	1690	1691	,
O	1692	1695	the
O	1696	1700	data
O	1701	1703	do
O	1704	1707	not
O	1708	1715	exclude
O	1716	1717	a
O	1718	1725	smaller
O	1726	1733	benefit
O	1734	1738	than
O	1739	1742	the
O	1743	1748	study
O	1749	1752	was
O	1753	1760	powered
O	1761	1763	to
O	1764	1770	detect
O	1771	1774	and
O	1775	1778	are
O	1779	1789	consistent
O	1790	1794	with
O	1795	1797	an
O	1798	1806	increase
O	1807	1809	in
O	1810	1814	both
O	1815	1822	disease
O	1822	1823	-
O	1823	1827	free
O	1828	1831	and
O	1832	1839	overall
O	1840	1848	survival
O	1849	1851	of
O	1852	1857	about
O	1858	1859	5
O	1859	1860	%
O	1861	1864	for
O	1865	1867	AD
O	1868	1876	compared
O	1877	1881	with
O	1882	1884	AC
O	1884	1885	.

O	1886	1893	Outcome
O	1894	1896	is
O	1897	1907	consistent
O	1908	1912	with
O	1913	1916	the
O	1917	1927	pathologic
O	1928	1936	complete
O	1937	1945	response
O	1946	1955	following
O	1956	1963	surgery
O	1963	1964	.
